Beat AML's adoption of e-Technologies

In a first-ever collaborative clinical trial to treat Acute Myeloid Leukemia (AML), the Beat AML Master Trial (Leukemia & Lymphoma Society) set out to streamline the conduct and management of the trial with e-technologies. Support of innovative trial design from the FDA allowed for the adoption of such technologies, increasing study efficiency and Oversight.

Since 2016, myClin has connected dozens of organizations in The Beat AML trial, providing data-driven oversight to improve participation, engagement and collaboration in clinical trials.

Access new research paper

Learn about Beat AML’s approach of adopting a Clinical Oversight Platform (myClin) to:

Provide real-time study data oversight
‍
Serve as “single source of truth” across the vendors, sites, CRO, and Sponsor
‍
Track compliance/engagement with study documents
‍
Centralize protocol training of sites for increased efficiency
‍
Streamline safety report distribution
‍
Remove the need for an in house IT department
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Learn about Beat AML’s approach to innovative trial design

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.